The decision most KL Grade III–IV patients face

"Told I need a knee replacement — is there anything worth trying first?" That question, raised daily in orthopaedic consultations, deserves a direct answer: for the right patient, yes.

Kellgren-Lawrence Grade III and IV osteoarthritis sits in a recognised treatment gap. Most cartilage repair procedures are designed for focal, isolated defects in otherwise healthy joints — they are not built for the diffuse, degenerative wear that defines high-grade OA. Yet total knee replacement (TKR) carries a real burden: major surgery, a rehabilitation period measured in months, and implant longevity that makes deferral clinically worthwhile wherever it is safely achievable.

ChondroFiller injection has been positioned as a structured pre-replacement option — with no published upper age ceiling and no defect-size limit — specifically for active patients in their 60s, 70s and beyond who are on a TKR pathway but want to attempt preservation first. The goal is not a cure. It is a clinically meaningful delay: reduced pain, restored function, and surgery deferred rather than cancelled.

One boundary is firm. Where no cartilage architecture remains to work with, joint replacement is the appropriate clinical answer, and ChondroFiller injection is a pre-replacement option, not a universal substitute for it.

Why Grade III–IV OA changes the rules for cartilage treatment

Kellgren-Lawrence grading gives a structural picture that explains why the surgical repair toolkit runs out of road at this stage. Grade III means significant joint-space narrowing, osteophyte formation, and often subchondral sclerosis — the bony plate beneath the cartilage beginning to thicken and harden in response to load. Grade IV means at least one compartment has reached bone-on-bone contact. In both cases, wear is diffuse and multi-surface: there is no single, contained lesion surrounded by healthy cartilage.

Every established cartilage restoration technique — MACI, ACI, OATS, AMIC — is designed around a contained focal defect with intact surrounding tissue. That surrounding cartilage is load-sharing scaffold; without it, a repair graft has no stable border to integrate into. Microfracture, now declining even for the smaller defects it was once first-choice for, lacks a coherent biological rationale at Grade III–IV: fibrocartilage fill breaks down within two to three years in a mechanically intact joint, and the conditions of advanced OA are less forgiving still.

The clinical question therefore shifts. At this stage it is no longer 'can we restore the cartilage?' — the structural prerequisites for that are gone. It becomes: 'can we protect what joint surface remains, reduce pain, and give the patient meaningful functional life before surgery becomes unavoidable?' That is the problem ChondroFiller injection is designed to address — and the reason its mechanism, a top-down additive scaffold applied to worn surfaces rather than implanted into a clean defect, is built differently from the surgical repair toolkit.

How the ChondroFiller injection works at this stage of OA

Once injected under ultrasound guidance into the fluid joint space — no theatre, no general anaesthetic — ChondroFiller begins gelling within minutes. The injectable collagen scaffold settles against worn articular surfaces and immediately starts doing something biologically different from a lubricant or a filler: it recruits the patient's own progenitor cells from the surrounding synovial environment, a process called matrix-induced chondrogenesis. Over six to twelve months, that populated scaffold is progressively remodelled into cartilage-like tissue.

The reliability of that process depends on the chemistry of the collagen. ChondroFiller is an acellular, murine-derived Type I collagen scaffold — CE-marked as a Class III medical device in 2013 — produced by a non-enzymatic, weak-acid extraction method that preserves the telopeptide sequences intact. Those sequences govern authentic physiological cross-linking: the scaffold gels and self-assembles in a way the joint can integrate naturally. Most commercial collagen products use pepsin-based processing, which cleaves those regions and reduces cross-linking capacity; the chemistry here is not incidental.

At KL Grade III–IV, the injection is deployed as a top-down additive cushion — coating degeneratively worn surfaces rather than being implanted into a surgically prepared bone bed. Because it does not require an intact surrounding cartilage margin, it is applicable precisely where surgical restoration techniques are not: the diffuse, multi-surface wear of advanced OA.

The contrast with other injectables is worth stating plainly. Hyaluronic acid functions as a lubricant, cleared from the joint within weeks, with no structural repair mechanism. Permanent synthetic hydrogels — such as polyacrylamide — provide mechanical cushioning but are non-biological; the body cannot populate or remodel them. ChondroFiller injection occupies different territory: a biological matrix the host joint can gradually convert, delivered in an outpatient setting without arthroscopic access.

What clinical evidence shows for high-grade knee OA

The functional improvement data across published ChondroFiller studies is consistent: multiple cohorts report knee IKDC score gains of approximately 30 points, well above the 16.7-point minimal clinically important difference — the threshold at which change becomes meaningful to the patient rather than merely statistically visible. The Jerosch et al. post-market clinical follow-up study, the longest-running published series, reports a mean gain of 32.4 IKDC points sustained and marginally increased at three-year follow-up, with patients reaching an absolute functional score of 80.

Structural MRI adds a parallel picture. MOCART scores — a validated measure of repair tissue quality, covering defect fill, scaffold integration, and surface congruency — range from 70 to 87 across published studies. In one series, MOCART progressed from 65.3 at four weeks to 81.6 at one year: evidence of a biological process maturing over time rather than a static filler settling in place.

For KL Grade IV knees specifically, Weninger et al. (2025) is the most directly applicable published data, examining outcomes for the ChondroFiller scaffold combined with cellular augmentation in the most advanced disease subgroup. The study reports functional and structural improvements — MOCART scores in the 70–87 range that characterise the broader literature — establishing it as the key clinical reference for the scaffold-plus-cells combination at Grade IV. More than 19,000 cases have been performed globally across more than a decade of use, with a reported complaint rate of approximately 0.06%.

The evidence base is primarily manufacturer-sponsored cohort and post-market follow-up studies. No published randomised controlled trial has evaluated ChondroFiller at KL Grade III–IV against a sham comparator, with TKA delay as the primary endpoint — that gap is a genuine limitation that prospective controlled trials will need to address.

The 2021 RESTORE trial (JAMA, n=288, KL Grade 2–3) found three weekly PRP injections no better than placebo for pain or cartilage volume at 12 months. That result is informative here because PRP provides no structural scaffold for cell recruitment; ChondroFiller's case for delay rests on a biological matrix the joint can populate and remodel — a mechanistic distinction the PRP failure makes concrete.

Combination protocols for advanced joint wear

For KL Grade III–IV disease, a single injectable rarely covers the full clinical picture. The worn cartilage surface and the pain-generating synovial lining are two distinct problems; the structured approach for advanced joint wear addresses them separately within a single outpatient appointment.

ChondroFiller injection — 2.3 mL, targeted to the bone ends — provides the regenerative scaffold: the biological matrix the joint can populate and remodel over time. Arthrosamid, a polyacrylamide hydrogel injected at 6 mL into the synovial membrane, addresses the lining where a significant proportion of pain signals originate. Arthrosamid is non-regenerative — the body cannot integrate or remodel it — and the two products serve genuinely different roles. Describing them as a blended treatment would misrepresent how they work: one is a cartilage-surface scaffold, the other a synovial cushion.

Where joint degradation is severe enough that a scaffold alone may be insufficient, autologous mesenchymal stem cells (MSCs) — sourced from bone marrow, adipose tissue, or ear cartilage — can be added to augment the ChondroFiller component. Weninger et al. (2025) provides published support for the scaffold-plus-cells approach specifically at Grade IV. Each component carries its own evidence base, but the three-way combination has not been validated as a complete regimen in randomised controlled trials — a genuine limitation that patients should understand before committing to it.

Beyond the initial treatment, structural preservation requires periodic review: annual MRI to track cartilage change, ongoing peptide supplementation as nutritional support, and a ChondroFiller injection top-up every two years. This is a long-term management commitment, not a one-off procedure, and that reality is a meaningful part of the decision.

Realistic expectations and who should consider it

Realistic candidacy narrows considerably from the outset. The patients most likely to benefit are those with KL Grade III or IV OA who still retain some joint architecture — meaning a cartilage surface, however degraded, remains in the affected compartment — and who are prepared to commit to a long-term maintenance programme of periodic imaging and repeat injections rather than a single definitive procedure. Age alone is not a disqualifying factor; active patients in their sixties and seventies represent the core cohort in published series.

The honest limit is bone-on-bone disease where no cartilage surface is salvageable. At that point the scaffold has nothing meaningful to integrate with, and joint replacement remains the appropriate — and necessary — step. ChondroFiller injection cannot reconstruct structural integrity that has been entirely lost.

For those who do qualify, the published benchmark is meaningful pain reduction and functional improvement — approximately 30 IKDC points, sustained to three years in the Jerosch et al. follow-up study — not reversal of osteoarthritis and not guaranteed avoidance of TKR. The aim is a structured interval of improved function while the scaffold matures progressively within the joint. Whether that interval extends over months or years depends on disease trajectory, adherence to the maintenance protocol, and the findings on annual MRI review.

Confirming candidacy requires imaging assessment and clinical evaluation. KL Grade III–IV on a scan is a necessary starting point, not a sufficient one — joint architecture, symptom pattern, and overall health all inform whether the injection pathway is appropriate for a given patient.

1. [1] Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. (2021). https://doi.org/10.1001/jama.2021.19415 https://doi.org/10.1001/jama.2021.19415